Brainsway Ltd. Stock Price, News & Analysis

BrainsWay Ltd. (NASDAQ: BWAY) announced plans to report its Q4 and full-year 2022 financial results on March 15, 2023, prior to U.S. market opening. The company will host a conference call at 8:30 AM ET to discuss these results and provide business updates. BrainsWay specializes in advanced noninvasive neurostimulation treatments for mental health disorders, utilizing its Deep TMS technology, which has received FDA clearance for multiple indications including major depressive disorder and obsessive-compulsive disorder. This announcement aims to inform stakeholders and enhance transparency regarding its operational performance.

Burlington, Mass. and Jerusalem, Feb. 23, 2023 - BrainsWay (NASDAQ: BWAY) announced that Dr. Colleen Hanlon received the 2023 International Brain Stimulation Early Career Award at the 5th International Brain Stimulation Conference in Lisbon, Portugal. This recognition highlights her significant contributions to brain stimulation and neuroscience. Dr. Hanlon, who previously served at Wake Forest University, has secured over $12 million in NIH funding and has authored a consensus paper on noninvasive neuromodulation in addiction. BrainsWay continues to lead in noninvasive neurostimulation treatments for mental health, with FDA-approved indications and ongoing clinical trials.

BrainsWay Ltd. has appointed Hadar Levy as the new Chief Executive Officer, succeeding Christopher R. von Jako, who stepped down to pursue other opportunities. Levy, who has been with the company since 2014, served previously as Chief Financial Officer and COO, bringing extensive operational and financial expertise. The transition aims to leverage Levy's experience to capitalize on growth opportunities in the noninvasive neurostimulation market. BrainsWay is recognized for its innovative Deep TMS technology, targeting mental health disorders, including major depression, OCD, and smoking addiction, with FDA-cleared indications.

BrainsWay Ltd. (NASDAQ & TASE: BWAY) has announced a significant leadership change, with Ami Boehm appointed as Chairman of the Board, succeeding co-founder David Zacut, M.D., who will now serve as a Director. Zacut co-founded the company in 2003 and played a crucial role in its development into a leader in noninvasive neurostimulation treatments for mental health disorders. Boehm, a seasoned professional in capital markets, brings extensive experience, having notably served as a partner at FIMI Opportunity Funds. This transition is expected to enhance shareholder value as BrainsWay pursues growth opportunities in its sector.

BrainsWay announced the publication of a comparative study validating the efficacy of its Deep Transcranial Stimulation (Deep TMS™) H1 and H7 coils for treating depression, published in The Journal of Clinical Investigation (JCI) Insight. The study involved 169 patients with treatment-resistant depression and showed that the H7 Coil demonstrated non-inferiority to the H1 Coil. Additionally, preliminary predictors for treatment optimization were identified. Notably, patients with high symptom severity had a 95% response rate with the H1 Coil. These findings emphasize the potential for personalized treatment approaches in mental health.

BrainsWay Ltd. (BWAY) announced that a major private insurance company in Washington state will extend coverage for its Deep Transcranial Magnetic Stimulation (Deep TMS™) for obsessive-compulsive disorder (OCD) starting February 3, 2023. This expansion affects approximately 2.2 million members and reduces the coverage criteria for major depressive disorder (MDD) from four to three failed medication trials. Since 2021, BrainsWay has significantly expanded its coverage, now reaching 90.5 million lives for OCD treatment, a substantial increase from 52.6 million.

BrainsWay Ltd. (NASDAQ: BWAY) announced the settlement of litigation with Neuronetics, Inc. in the District of Delaware. The settlement terms remain confidential, and BrainsWay did not admit liability. CEO Christopher von Jako emphasized the company's focus on advancing its Deep TMS™ therapy for patients. BrainsWay is recognized for its innovative neurostimulation treatments for various mental health disorders, holding three FDA clearances for its technology. The company remains committed to expanding the use of Deep TMS and conducting further clinical trials.

BrainsWay Ltd. (NASDAQ: BWAY) announced that independent Director Yossi Ben Shalom purchased 147,500 ADRs, totaling $277,300, at an average price of $1.88 each. This investment underscores his confidence in BrainsWay's strategic vision and its Deep TMS technology, which has proven effective in treating multiple mental health disorders. Other board members have also made similar open market purchases, reflecting a collective bullish outlook. BrainsWay continues to expand its research and clinical trials to enhance its market position in non-invasive neurostimulation treatments.

BURLINGTON, Mass. and JERUSALEM, Nov. 28, 2022 – BrainsWay Ltd. (NASDAQ: BWAY) reported significant open market stock purchases by its Chairman, Dr. David Zacut, and independent Director, Avner Hagai. Dr. Zacut acquired 431,797 shares for 1,607,676 NIS (approximately 3.72 NIS per share), increasing his stake to 6.71%. Mr. Hagai purchased 403,312 shares for 1,581,048 NIS (approximately 3.92 NIS per share), raising his ownership to 6.49%. Both purchases reflect confidence in the company's growth prospects and favorable industry trends.